6-羟基-2-甲基喹啉 | 613-21-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-羟基-2-甲基喹啉
• 中文别名: 2-甲基-6-羟基喹啉
• 英文名称: 6-hydroxyquinaldine
• 英文别名: 2-methylquinolin-6-ol；6-hydroxy-2-methylquinoline；2-methyl-6-hydroxyquinoline；6-hydroxy-2-quinaldine；2-methylquinoline-6-ol
• CAS: 613-21-8
• 化学式: C₁₀H₉NO
• mdl: MFCD00047600
• 分子量: 159.188
• InChiKey: USSQQASIZNTRAJ-UHFFFAOYSA-N

物化性质

• 熔点：
  214.0 to 218.0 °C
• 沸点：
  284.68°C (rough estimate)
• 密度：
  1.1665
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  性质与稳定性：在常温常压下，该物质不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 储存条件：
  贮存： 将密封的容器储存在阴凉、干燥的地方。

SDS

Name:	2-Methylquinolin-6-ol 97% Material Safety Data Sheet
Synonym:	6-Hydroxyquinaldin
CAS:	613-21-8

Section 1 - Chemical Product MSDS Name:2-Methylquinolin-6-ol 97% Material Safety Data Sheet
Synonym:6-Hydroxyquinaldin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
613-21-8	2-Methylquinolin-6-ol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 613-21-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 198 - 200 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9NO
Molecular Weight: 159

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 613-21-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Methylquinolin-6-ol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 613-21-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 613-21-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 613-21-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-羟基-2-甲基喹啉 在 喹啉 、 sodium hydroxide 、 四丁基溴化铵 、 sodium methylate 作用下， 以 甲醇 、 氯仿 、 乙腈 、 苯 为溶剂， 反应 47.0h， 生成 3-Butoxy-4-[1-methyl-6-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-1H-quinolin-(2E)-ylidenemethyl]-cyclobut-3-ene-1,2-dione
  参考文献：
  名称：

  Synthesis of New Cholesterol- and Sugar-Anchored Squaraine Dyes:  Further Evidence of How Electronic Factors Influence Dye Formation

  摘要：

  Synthesis of new quinaldine-based squaraine dyes linked to cellular recognition elements that exhibit near-infrared absorption (> 740 nm) are described. Both product analysis and theoretical calculations substantiate the interesting electronic effects of various substituents in the dye formation reaction. These results are useful in the synthesis of symmetrical and unsymmetrical squaraine dyes that can have potential biological and photodynamic therapeutical applications.

  DOI：

  10.1021/ol052639j
• 作为产物：
  描述：

  1,2,3,4-四氢喹哪啶 在 glucose dehydrogenase 、 葡萄糖 、 cytochrome P₄₅₀ enzyme CYP₁₀₂A₁ A₈₂M/F₈₇A/H₁₇₁L/E₂₆₇F/Q₃₀₇H/N₃₁₉Y mutant 、 cytochrome P₄₅₀ enzyme CYP₁₀₂A₁ R₄₇L/Y₅₁F/H₁₇₁L/I₂₆₃G/Q₃₀₇H/N₃₁₉Y/A₃₂₈L mutant 、 C₂₁H₂₅N₇O₁₇P₃^(3-)*2H⁽¹⁺⁾*Na⁽¹⁺⁾ 作用下， 以 aq. phosphate buffer 、 乙醇 为溶剂， 反应 64.0h， 生成 6-羟基-2-甲基喹啉
  参考文献：
  名称：

  CYP102A1（P450BM3）在喹啉和四氢喹啉的氧化中的多功能氧化酶活性。

  摘要：

  四氢喹啉，喹啉和二氢喹啉酮是药物分子中常见的核心基序。筛选细胞色素P450酶CYP102A1（P450BM3）的48个变体文库，然后基于初始命中的突变-选择性相关性进行定向诱变，使取代的四氢喹啉，喹啉和3,4-二氢-2-羟基化在两个环的大部分位置上，喹啉酮类以合成相关的比例（1.5 g L -1 天-1）。还观察到其他氧化酶活性，例如C-C键去饱和，芳构化和C-C键形成。这些酶变体在关键的活性位点残基S72，A82，F87，I263，E267，A328和A330处具有突变，为合成和药物发现这些构建基分子的氧官能化衍生物提供了直接且可持续的途径。

  DOI：

  10.1002/anie.201904157

文献信息

• [EN] BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS<br/>[FR] ANALOGUES D’ARYLSPHINGOSINE-1-PHOSPHATE BICYCLIQUES
  申请人：BIOGEN IDEC INC

  公开号：WO2011017561A1

  公开（公告）日：2011-02-10

  Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.

  提供具有在一个或多个SlP受体上拮抗活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后可以在SlP受体上表现为拮抗剂。
• Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
  申请人：——

  公开号：US20030166644A1

  公开（公告）日：2003-09-04

  Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

  使用化合物抑制激素敏感性脂肪酶，包括这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及新化合物。目前的化合物是激素敏感性脂肪酶的抑制剂，可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。
• Assembly of Diversely Substituted Quinolines via Aerobic Oxidative Aromatization from Simple Alcohols and Anilines
  作者：Jixing Li、Jinlong Zhang、Huameng Yang、Gaoxi Jiang

  DOI：10.1021/acs.joc.6b03064

  日期：2017.3.17

  acid catalytic system has been established, providing a direct approach for the preparation of diverse substituted quinoline derivatives in high yields with wide functional group tolerance. Practically, the protocol can be easily scaled up to gram-scale and was utilized in the concise formal synthesis of a promising herbicide candidate.

  建立了在Pd（OAc）2 / 2,4,6-Collidine /Brønsted酸催化体系下简单脂肪族醇和苯胺的需氧氧化芳构化，为直接制备高产率的多种取代的喹啉衍生物提供了直接的方法。广泛的功能组耐受性。实际上，该方案可以轻松按比例放大至克级，并用于有希望的除草剂候选物的简明正式合成中。
• Nickel-Catalyzed Alkoxy-Alkyl Interconversion with Alkylborane Reagents through C−O Bond Activation of Aryl and Enol Ethers
  作者：Lin Guo、Xiangqian Liu、Christoph Baumann、Magnus Rueping

  DOI：10.1002/anie.201607646

  日期：2016.12.5

  A nickel‐catalyzed alkylation of polycyclic aromatic methyl ethers as well as methyl enol ethers with B‐alkyl 9‐BBN and trialkylborane reagents that involves the cleavage of stable C(sp2)−OMe bonds is described. The transformation has a wide substrate scope and good chemoselectivity profile while proceeding under mild reaction conditions; it provides a versatile way to form C(sp2)−C(sp3) bonds that

  描述了镍催化的多环芳族甲基醚以及甲基烯醇醚与B-烷基9-BBN和三烷基硼烷试剂的反应，涉及到稳定C（sp 2）-OMe键的裂解。该转化具有较宽的底物范围和良好的化学选择性，同时可在温和的反应条件下进行；它提供了一种形成C（sp 2）-C（sp 3）键的通用方法，该方法不会遭受β-氢化物消除。此外，提出了通过裂解惰性C-O键进行的选择性和顺序烷基化过程，以证明该方法的优势。
• AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1844768A1

  公开（公告）日：2007-10-17

  The present invention provides a compound represented by the following formula (I): [wherein, A represents a group of the following formula (A-1): etc., R1 and R2 each independently represent a hydrogen atom etc., Z represents CR3 etc., W represents CR4 etc., Q represents CR5 etc., R3, R4 and R5 each independently represent a hydrogen atom etc., Y represents an oxygen atom or sulfur atom, X represents an oxygen atom etc. and B represents an optionally substituted aryl group or optionally substituted heteroaryl group], the prodrug thereof or the pharmaceutically acceptable salt thereof for preventing or treating various diseases such as hypertesion, cerebral stroke, cardiac failure, etc.

  本发明提供了以下式（I）所表示的化合物： [其中，A表示以下式（A-1）的基团： 等等，R1和R2分别独立表示氢原子等，Z表示CR3等，W表示CR4等，Q表示CR5等，R3、R4和R5分别独立表示氢原子等，Y表示氧原子或硫原子，X表示氧原子等，B表示可选择地取代的芳基或可选择地取代的杂环基]，其前药或其药学上可接受的盐，用于预防或治疗高血压、脑卒中、心力衰竭等各种疾病。

表征谱图